FDA Tackles Nanotechnology Impact on Drug Regulation
By Marie Powers
Friday, August 10, 2012
While the rest of the biotech world seems to embrace the arrival of nanotechnology in drug development, the FDA is still seeking to understand the nuances of products that contain nanoscale materials.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.